Adenocarcinoma of the lung

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Retrieved on: 
Friday, July 30, 2021
Cancer, Clinical medicine, Health, Lung cancer, Gastrointestinal cancer, Epithelium, Oncology, Squamous cell carcinoma, Esophageal cancer, Nivolumab, Adenocarcinoma of the lung

Esophageal squamous cell carcinoma and adenocarcinoma are the two main histological subtypes of esophageal cancer.

Key Points: 
  • Esophageal squamous cell carcinoma and adenocarcinoma are the two main histological subtypes of esophageal cancer.
  • Esophageal squamous cell carcinoma is the main subtype in China, accounting for 90% of all esophageal cancer.
  • For patients with advanced or metastatic esophageal squamous cell carcinoma, the current standard first-line treatment is platinum-based chemotherapy, but the 5-year overall survival rate is less than 20%.
  • In March 2021, toripalimab received Breakthrough Therapy Designation for the first-line treatment of advanced mucosal melanoma by the NMPA.

LUMAKRAS™ (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Friday, June 4, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Lung cancer, Breakthrough therapy, Drugs, Orphan drugs, Chemical compounds, Health sciences, Non-small-cell lung carcinoma, KRAS, Sotorasib, Treatment of lung cancer, Adenocarcinoma of the lung

The recent approval of LUMAKRAS unlocks the first FDA-approved treatment option for patients with previously treated advanced or metastatic KRAS G12C-mutant NSCLC.

Key Points: 
  • The recent approval of LUMAKRAS unlocks the first FDA-approved treatment option for patients with previously treated advanced or metastatic KRAS G12C-mutant NSCLC.
  • As a provider of this key treatment, Onco360 is committed to supporting the highly specialized needs of NSCLC patients.
  • When considering all stages and histologic subtypes of the disease, the five-year overall survival (OS) of lung cancer is 21.7%.
  • Unfortunately, 56% of lung cancer patients have metastatic disease upon initial diagnosis.

FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

Retrieved on: 
Friday, May 28, 2021
Lung cancer, Branches of biology, Biology, KRAS, Cancer, Non-small-cell lung carcinoma, Mutation, Ras GTPase, Adenocarcinoma of the lung, Pancreatic cancer

This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers.

Key Points: 
  • This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers.
  • Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it.
  • KRAS is a type of mutation in a group of genes that help regulate cell growth and division.
  • Lumakras should be withheld if patientsdevelopsymptoms of interstitial lung disease and permanently discontinued if interstitial lung disease is confirmed.

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Friday, May 21, 2021
Lung cancer, Organic compounds, Chemical compounds, Quinazolines, Chemistry, Tyrosine kinase inhibitors, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Adenocarcinoma of the lung, T790M, Icotinib

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.Molecular Cancer Therapeutics.2013; Feb; 12(2):220-9.\n3Key Statistics in Lung Cancer.

Key Points: 
  • EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.Molecular Cancer Therapeutics.2013; Feb; 12(2):220-9.\n3Key Statistics in Lung Cancer.
  • Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
  • Accessed May 2021.\n14Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer.
  • Accessed May 2021.\n15Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award

Retrieved on: 
Friday, February 19, 2021
Cancer, Epidermal growth factor receptor, Non-small-cell lung carcinoma, Lung cancer, Branches of biology, Clinical medicine, Gefitinib, Adenocarcinoma of the lung

WASHINGTON, Feb. 19, 2021 /PRNewswire/ --Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award.

Key Points: 
  • WASHINGTON, Feb. 19, 2021 /PRNewswire/ --Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award.
  • The ultimate goal of this research is to transform EGFR-positive non-small cell lung cancer into a chronic, manageable condition.
  • As a mechanism of resistance to EGFR inhibitors, cancers can change histology from adenocarcinoma to small cell or squamous cell lung cancer.
  • "We are deeply grateful for the honor of receiving these awards and the pleasure of working with LUNGevity Foundation and the EGFR Resisters to help improve outcomes for all patients with lung cancer harboring an EGFR mutation," says Dr. Yu.

Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

Retrieved on: 
Monday, June 22, 2020
Drugs, Lung cancer, Clinical medicine, Bristol-Myers Squibb, KRAS, Medicine, Nivolumab, Adenocarcinoma of the lung, Treatment of lung cancer

Despite discovering the KRAS mutation over 30 years ago, little progress has been made in KRAS+ directed treatments.

Key Points: 
  • Despite discovering the KRAS mutation over 30 years ago, little progress has been made in KRAS+ directed treatments.
  • The work under Dr. Rajwanth Veluswamys leadership at the Icahn School of Medicine is an important step towards determining if rigosertib, as a RAS-mimetic, can change that.
  • The investigator-initiated trial is an open-label, dose-escalating Phase 1 study followed by a Phase 2a dose-expansion phase to study the combination of oral rigosertib and nivolumab in metastatic KRAS+ lung adenocarcinoma patients who have progressed on standard frontline treatment.
  • The study will explore efficacy of the combination in this common lung cancer subset and will alsodetermine if rigosertib may restore sensitivity to the PD-1 blockade.

IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8th

Retrieved on: 
Sunday, September 8, 2019
Lung cancer, Neoplasms, Non-small-cell lung carcinoma, KRAS, Adenocarcinoma of the lung, Clinical medicine, Cancer, Treatment of lung cancer

There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.

Key Points: 
  • There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.
  • Of the 34 patients, only nine (26.5 percent) reported treatment-related adverse events of grade one or two.
  • "KRAS G12C mutant lung adenocarcinoma is one of the largest subsets of NSCLC potentially amenable to targeted therapies.
  • The announcement was made at the International Association for the Study of Lung Cancer World Conference on Lung Cancer in Barcelona, Spain by JTO editor Dr. Alex Adjei.

IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8th

Retrieved on: 
Sunday, September 8, 2019
Clinical medicine, Medicine, Non-small-cell lung carcinoma, Lung cancer, KRAS, Adenocarcinoma of the lung, Targeted therapy, Health, Treatment of lung cancer

Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Key Points: 
  • Note: This is a summary of research presented this morning at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.
  • There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLC patients enrolled.
  • "KRAS G12C mutant lung adenocarcinoma is one of the largest subsets of NSCLC potentially amenable to targeted therapies.
  • The announcement was made at the International Association for the Study of Lung Cancer World Conference on Lung Cancer in Barcelona, Spain by JTO editor Dr. Alex Adjei.

Health Canada approves TECENTRIQ® (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer

Retrieved on: 
Wednesday, May 29, 2019
Lung cancer, Cancer, Neoplasms, Clinical medicine, Non-small-cell lung carcinoma, Adenocarcinoma of the lung, Atezolizumab, Oncology, Small-cell carcinoma, Combined small-cell lung carcinoma

Non-squamous lung cancer includes lung adenocarcinoma and large cell lung cancer, and makes up around 55% of all NSCLCs.6The estimated five-year survival rate for patients with metastatic NSCLC is 2-13%.7

Key Points: 
  • Non-squamous lung cancer includes lung adenocarcinoma and large cell lung cancer, and makes up around 55% of all NSCLCs.6The estimated five-year survival rate for patients with metastatic NSCLC is 2-13%.7
    "Immunotherapies like TECENTRIQ represent a cornerstone in lung cancer treatment, and are crucial to providing personalized treatment approaches for many patients," says Dr. Mark Vincent, Medical Oncologist.
  • "Clinical data support this combination as a first-line therapy that can extend survival for certain lung cancer patients."
  • The Canadian Cancer Statistics indicate that approximately half are diagnosed at stage 4, a late stage,"9 says Shem Singh, Executive Director, Lung Cancer Canada.
  • Our goal is to provide an effective treatment option for every person diagnosed with lung cancer.

American Lung Association and the Ad Council Launch Spanish Language PSA Campaign to Increase Awareness of Lung Cancer Screening among the Hispanic Community

Retrieved on: 
Tuesday, November 13, 2018
Lung cancer, Cancer, Medicine, Health, Cancer screening, Health effects of tobacco, Lung cancer screening, RTT, Screening, Lung, Lung Cancer Alliance, Adenocarcinoma of the lung

NEW YORK, Nov. 13, 2018 /PRNewswire/ --To raise public awareness of lung cancerthe leading cancer killer of women and menduring Lung Cancer Awareness Month, the American Lung Association's LUNG FORCE initiative and the Ad Council today launched Spanish language messaging for its "Saved By The Scan" campaign to educate the Hispanic community about the lifesaving lung cancer screening.

Key Points: 
  • NEW YORK, Nov. 13, 2018 /PRNewswire/ --To raise public awareness of lung cancerthe leading cancer killer of women and menduring Lung Cancer Awareness Month, the American Lung Association's LUNG FORCE initiative and the Ad Council today launched Spanish language messaging for its "Saved By The Scan" campaign to educate the Hispanic community about the lifesaving lung cancer screening.
  • The low-dose CT scan can detect lung cancer in the early stages, before symptoms arise, when the disease is more curable.
  • This new Spanish-language campaign aims to raise awareness of the benefits of early detection through lung cancer screening and drive high-risk individuals to take a lung cancer screening eligibility quiz at SalvaTuPulmon.org ( SavedByTheScan.org in English).
  • The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer, the leading cancer killer of women and men.